Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833972 | 1.00 | PLA2G2A (0.47) | PLA2G2APLA2G5FOLH1CTSKALDH1A1 | |
| SCHEMBL23833896 | 0.95 | PLA2G2A (0.47) | PLA2G2APLA2G5FOLH1CTSKALDH1A1 | |
| SCHEMBL23833899 | 0.95 | PLA2G2A (0.47) | PLA2G2APLA2G5FOLH1CTSKALDH1A1 | |
| SCHEMBL23849263 | 0.90 | BIRC2 (0.47) | CTSK | |
| SCHEMBL23834433 | 0.87 | PLA2G2A (0.39) | PLA2G2APLA2G5FOLH1CTSK | |
| SCHEMBL23834434 | 0.87 | PLA2G2A (0.39) | PLA2G2APLA2G5FOLH1CTSK | |
| SCHEMBL23849403 | 0.85 | BIRC2 (0.47) | CTSKPLA2G2C | |
| SCHEMBL23849171 | 0.84 | CTSK (0.44) | CTSKPLA2G2C | |
| SCHEMBL23834042 | 0.82 | PLA2G2A (0.50) | PLA2G2APLA2G5ALDH1A1 | |
| SCHEMBL23834040 | 0.82 | PLA2G2A (0.50) | PLA2G2APLA2G5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-18 | — | — | US | disclosed |
| WO-2021188620-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151034-A1 | PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | ASNS, GLUL, GNMT | PLA2G2A 3615/4885PLA2G5 1544/4885FOLH1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.